glp-1 cardiovascular outcomes trial august 2025 Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology GLP-1受容体作動薬 | うるうクリニック港南台 quantity-discount:exclude Size:12.5 oz

glp-1 cardiovascular outcomes trial august 2025 Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology GLP-1受容体作動薬 | うるうクリニック港南台 quantity-discount:exclude Size:12.5 oz

GLP-1受容体作動薬 | うるうクリニック港南台

Lincoff AM, SELECT Trial Investigators

quantity-discount:exclude

Size:12.5 oz

Predicted coverage changes post-approval: Based on the coverage expansion pattern when Wegovy gained FDA approval for obesity in 2021, we expect: 60-70% of large-employer commercial plans to cover GLP-1s for NASH within 6 months of FDA approval 30-40% of marketplace plans to add coverage within 12 months Medicare Part D to cover for NASH (but not for obesity, due to the statutory weight-loss drug exclusion) Medicaid coverage to remain state-specific, with 15-20 states adding NASH coverage within 18 months Prior authorization will still be required, but approval rates will flip from 25% (current off-label rate) to 70-80% (typical for newly approved indications)